Qiagen N.V. (ETR: QIA)

Germany flag Germany · Delayed Price · Currency is EUR
44.94
+0.29 (0.65%)
Jan 17, 2025, 5:35 PM CET
5.51%
Market Cap 9.93B
Revenue (ttm) 1.76B
Net Income (ttm) 83.32M
Shares Out n/a
EPS (ttm) 0.37
PE Ratio 119.23
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 853,874
Average Volume 478,874
Open 44.75
Previous Close 44.65
Day's Range 44.44 - 44.96
52-Week Range 36.59 - 45.02
Beta 0.40
RSI 66.59
Earnings Date Feb 3, 2025

About Qiagen

Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for n... [Read more]

Sector Healthcare
Founded 1984
Employees 5,531
Stock Exchange Deutsche Börse Xetra
Ticker Symbol QIA
Full Company Profile

Financial Performance

In 2023, Qiagen's revenue was $1.97 billion, a decrease of -8.23% compared to the previous year's $2.14 billion. Earnings were $341.30 million, a decrease of -19.35%.

Financial numbers in USD Financial Statements

News

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approxima...

4 days ago - Business Wire

Qiagen NV (QGEN) Announces Fourth Quarter 2024 Results Release and Conference Call

Qiagen NV (QGEN) Announces Fourth Quarter 2024 Results Release and Conference Call

5 days ago - GuruFocus

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt...

5 days ago - Wallstreet:Online

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, ...

5 days ago - Business Wire

Qiage announces $300M buyback plan

Qiagen N.V. announces plan to return $300M to shareholders through synthetic share repurchase, part of $1B commitment by 2028.

7 days ago - Seeking Alpha

Qiagen NV Announces $300 Million Synthetic Share Repurchase Plan

Qiagen NV Announces $300 Million Synthetic Share Repurchase Plan

8 days ago - GuruFocus

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share repurc...

8 days ago - Wallstreet:Online

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 mi...

8 days ago - Business Wire

EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase

EQS-Ad-hoc: QIAGEN N.V. / Key word(s): Share Buyback QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase 12-Jan-2025 / 18:55 CET/CEST Disclosu...

8 days ago - Wallstreet:Online

Qiagen NV (QGEN) Enhances QIAcuity Digital PCR System with Advanced Multiplexing Capabilities

Qiagen NV (QGEN) Enhances QIAcuity Digital PCR System with Advanced Multiplexing Capabilities

10 days ago - GuruFocus

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in t...

10 days ago - Wallstreet:Online

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system wi...

10 days ago - Business Wire

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by...

11 days ago - Wallstreet:Online

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gast...

11 days ago - Business Wire

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

REDWOOD CITY, Calif. & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery o...

13 days ago - Business Wire

EY wins first Dax audit client since Wirecard scandal

Big Four firm handed mandate by biotech group Qiagen despite ban on taking on listed German companies

4 weeks ago - Financial Times

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new featu...

5 weeks ago - Business Wire

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 C...

6 weeks ago - Business Wire

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year inv...

7 weeks ago - Wallstreet:Online

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a ne...

7 weeks ago - Business Wire

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custo...

7 weeks ago - GlobeNewsWire

Wellington Management Group LLP's Strategic Acquisition of Qiagen NV Shares

Wellington Management Group LLP's Strategic Acquisition of Qiagen NV Shares

2 months ago - GuruFocus

Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript

Qiagen N.V. (NYSE:QGEN) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ETCompany ParticipantsJohn Gilardi - VP, Head of Corporate Communications...

2 months ago - Seeking Alpha

Diagnostics firm Qiagen reports rise in third-quarter revenue

Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.

2 months ago - Reuters

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successf...

2 months ago - GlobeNewsWire